Home/Boundless Bio/Chris Hassig, Ph.D.
CH

Chris Hassig, Ph.D.

Chief Scientific Officer

Boundless Bio

Therapeutic Areas

Boundless Bio Pipeline

DrugIndicationPhase
BBI-355Oncogene-amplified solid tumorsPhase 1